Quick Summary: Obviousness-type double patenting (ODP) is a judicially created doctrine that prevents patent holders from stretching exclusivity by obtaining […]
The Double Patenting Trap: How Pharma Brands Accidentally Invalidate Their Own Moats Read Post »
The answer to whether you should use PAT-INFORMED to find drug patent loss-of-exclusivity dates depends entirely on who you are,
PAT-INFORMED for Drug LOE Dates: What Procurement Agencies and Analysts Get Wrong Read Post »
Between September 2023 and May 2025, the Federal Trade Commission challenged more than 600 patent listings in the FDA’s Orange
Orange Book Delisting Wave: What the FTC Crackdown Means for Your Pipeline Read Post »
When a patient types “Is there a cheaper alternative to Eliquis?” into ChatGPT, they expect an accurate, up-to-date answer. What
Do LLMs Recommend Branded Drugs More Often Than Generics? Read Post »
The Drug Price Competition and Patent Term Restoration Act of 1984, universally called Hatch-Waxman, created the legal architecture that now
The Hatch-Waxman Roadmap: How ANDA Filings and Patent Challenges Really Work Read Post »
The primary compound patent on a drug is the one the industry talks about. It sets the nominal expiry date
Four Secondary Patent Types That Extend Drug Exclusivity Beyond the Primary Patent Read Post »
There’s a particular moment in modern medicine that produces more confusion than almost anything else in healthcare. It happens somewhere
The day a competitor files a Paragraph IV certification against your lead molecule, you have 45 days to file suit
There is a narrow pricing band in pharmaceuticals where the math actually works. Price too high and payers route patients
Sign in or create a free account to read this DrugPatentWatch article
